Form 4: Arvinas CSO Awarded Significant Equity and Options

Arvinas' Chief Scientific Officer, Angela M. Cacace, received a grant of 45,000 restricted stock units and options to purchase 67,000 shares of common stock.

Summary

• Angela M. Cacace, Chief Scientific Officer of ARVINAS, INC. (ARVN), was granted 45,000 Restricted Stock Units (RSUs) on February 26, 2026.
• Each RSU represents a contingent right to receive one share of common stock upon settlement for no consideration.
• The RSUs will vest over four years, with one-quarter vesting on February 26, 2027, February 26, 2028, February 26, 2029, and February 26, 2030, contingent on continued service.
• Cacace also received options to purchase 67,000 shares of common stock on February 26, 2026, with an exercise price of $13.38 per share.
• The options vest over four years: one-quarter on February 26, 2027, with the remainder vesting in equal monthly installments through February 26, 2030, subject to continued service.
• Following these transactions, Cacace beneficially owns 192,623 shares of common stock directly and 67,000 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies the company's commitment to retaining key scientific leadership and aligning executive incentives with long-term shareholder value creation.

Positives

• The grant of restricted stock units and stock options aligns the Chief Scientific Officer's long-term interests with those of shareholders, promoting retention and performance.
• The equity awards are part of a standard compensation package, indicating continued commitment to key executive talent.

Future Outlook

The vesting schedules for both the restricted stock units and stock options extend through February 2030, indicating a long-term incentive structure designed to retain the Chief Scientific Officer and align her performance with the company's future success.

Industry Context

StockSavvy.ai notes that the granting of equity awards, such as restricted stock units and stock options, is a standard and widely adopted practice in the biotechnology and pharmaceutical industries for executive compensation. This strategy is crucial for attracting, retaining, and motivating key scientific and leadership talent, whose expertise is vital for long-term drug development and innovation. These awards typically vest over several years, creating a strong incentive for executives to contribute to sustained company growth and shareholder value.

Comparison to Industry Standards

• The structure of multi-year vesting for both RSUs and stock options is consistent with executive compensation practices observed at comparable biotech firms like Moderna (MRNA) or BioNTech (BNTX), where long-term incentives are critical for retaining scientific leadership.
• The exercise price of $13.38 for the stock options is set at the market price on the grant date, which is a common practice to ensure that the options gain value only if the company's stock price appreciates, directly linking executive reward to shareholder returns.

Stakeholder Impact

• Shareholders: The equity grants align the Chief Scientific Officer's financial interests with shareholder value creation, potentially leading to more focused long-term strategic decisions.
• Employees: May signal stability in leadership and a commitment to retaining key talent within the organization.

Next Steps

• Continued service of Angela M. Cacace with Arvinas, Inc. to fulfill vesting conditions for RSUs and stock options.
• Vesting of RSUs and stock options will occur on scheduled dates through February 2030.

Key Dates

Recommendation

This Form 4 reports routine equity compensation for a key executive, which is a positive for aligning management incentives with shareholder interests but does not fundamentally alter the company's investment thesis or warrant a change in a seasoned investor's current position based solely on this filing.

Keywords

ARVINAS, ARVN, Form 4, insider transaction, equity grant, restricted stock units, stock options, executive compensation, Chief Scientific Officer